NSEDCP
APLS

NJ State Employees Deferred Compensation Plan’s Apellis Pharmaceuticals APLS Stock Holding History

NJ State Employees Deferred Compensation Plan’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-6,000
Closed -$230K – 476
2024
Q2 		$230K Hold
6,000
– – 0.03% 403
2024
Q1 		$353K Hold
6,000
– – 0.04% 347
2023
Q4 		$359K Hold
6,000
– – 0.05% 349
2023
Q3 		$228K Hold
6,000
– – 0.03% 397
2023
Q2 		$547K Hold
6,000
– – 0.08% 258
2023
Q1 		$396K Hold
6,000
– – 0.06% 327
2022
Q4 		$310K Buy
+6,000
New +$318K 0.05% 355

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

NJ State Employees Deferred Compensation Plan's APLS Position: Q3 2024 in Review

NJ State Employees Deferred Compensation Plan sold out of Apellis Pharmaceuticals (APLS) in Q3 2024, closing a stake of 6,000 shares — an estimated $230K sold.

NJ State Employees Deferred Compensation Plan first reported a position in APLS in Q4 2022 and held it in 7 quarters. The position peaked at $547K in Q2 2023. 265 funds tracked by Wall St. Rank hold APLS as of Q3 2024.

  • NJ State Employees Deferred Compensation Plan reported no remaining Apellis Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • NJ State Employees Deferred Compensation Plan sold 6,000 Apellis Pharmaceuticals shares in Q3 2024, an estimated $230K.
  • NJ State Employees Deferred Compensation Plan first reported a position in Apellis Pharmaceuticals in Q4 2022 and held it in 7 quarters.
  • NJ State Employees Deferred Compensation Plan's Apellis Pharmaceuticals position peaked at $547K in Q2 2023.
  • 265 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2024.

Based on NJ State Employees Deferred Compensation Plan's 13F filing for Q3 2024, filed 4 Nov 2024.